**Supplementary Table S6. Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Idelalisib\*****N = 146** | **Copanlisib\*****N = 244** | **Duvelisib\*****N = 442** | **Umbralisib\*****N = 371** | **Linperlisib****N=84** |
| **Efficacy (FL)** |  |  |  |  |  |
| ORR, % | 57 | 59 (FL) | 42 (FL) | 45.3 (FL) | 79.8 (FL) |
| Median PFS (months) | 11 | 12.5 | 9.5 | 10.6 (FL) | 13.4 (FL) |
| 12-month OS rate  | 80% | NA | 77%  | NA | 91.4% (FL) |
| Median OS (months) | 20.3  | 42.6 | 28.9 | NA | Not reached at 42 months follow up  |
| **Safety\*** |  |  |  |  |  |
| Grade ≥ 3 AE | 71% | 85% | 84% | 51% | 66.7% |
| SAEs | 50% | 51% | 65% | 26% | 40.5% |
| Discontinuations due to AE | 23% | 24% | 35% | 15% | 17.9% |
| Dose reduction due to AE | 41% | 24% | 23% | 10% | 14.3% |
| Dose interruption due to AE | 41% | 64% | 64% | 45% | 42.9% |
| Grade ≥ 3 Infection | 23% | 23% | 27% | 20% | 21.4% |
| Grade ≥ 3 Neutropenia | 28% | 29% | 43% | 17% | 15.5% |
| Grade ≥ 3 Diarrhea/Colitis | 14% | 5% | 23% | 7% | 1.2% |
| Grade ≥ 3 AST/ALT increase | 18% | 2% | 8% | 7% | 1.2% |
| Grade ≥ 3 Rash | 4% | 2% | 9% | 3% | 1.2% |
| Grade ≥ 3 Non-infectious pneumonitis  | 4% | 5% | 5% | 1% | 3.6% |
| Grade ≥ 3 Hyperglycemia | - | 34% | - | - | 1.2% |
| Grade ≥ 3 Hypertension | - | 29% | - | - | - |

Note: \*Safety data were adopted from FDA Introductory Comments of the Oncologic Drugs Advisory Committee Meeting in April 2022. FL indicates that follicular lymphoma sub-analyses were available.

**Abbreviations**: AEs, adverse events; CR, complete response; FL, follicular lymphoma; ORR, objective response rate; NA, not analyzed; OS, overall survival; PFS, progression-free survival; SAEs, serious adverse events.